Clopidogrel Resistance and Embolism in Carotid Artery Stenting

• Status: Unknown status
• Trial end date: 2017-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of the ticlopidine + ginko biloba compared to clopidogrel in clopidogrel resistant patients undergoing carotid artery stent placement. The investigators hypothesized that ticlopidine + ginko biloba is superior than clopidogrel in terms of post-stent ischemic lesions in these patients without serious complications.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Samsung Medical Center
• Collaborator: Yuyu Pharma, Inc.
• Treatments: Clopidogrel; Ticlopidine

Criteria

Inclusion Criteria:

• Patients scheduled for stent implantation due to carotid stenosis

• Patients resistant to clopidogrel defined by platelet inhibition rate <20% measured by Verify Now before carotid stenting

• Patients with informed consent

Exclusion Criteria:

• Antiplatelet therapy other than aspirin, clopidogrel, or ticlopidine

• Unable to perform MRI scans

• Patients with hematologic abnormalities including neutrophil <1500/ul, platelet <100,000/uL, or AST/ALT >120 U/L

• Unsuitable for participation